Cargando…

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial

PURPOSE: Immunocompromised patients have a potentially increased risk for progression to severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis examined outcomes among immunocompromised participants in the MOVe-OUT trial. METHODS: In phase 3 of MOVe-OUT, non-hospitalized at-...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Matthew G., Strizki, Julie M., Brown, Michelle L., Wan, Hong, Shamsuddin, Hala H., Ramgopal, Moti, Florescu, Diana F., Delobel, Pierre, Khaertynova, Ilsiyar, Flores, José F., Fouche, Leon F., Chang, Shan-Chwen, Williams-Diaz, Angela, Du, Jiejun, Grobler, Jay A., Paschke, Amanda, De Anda, Carisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844162/
https://www.ncbi.nlm.nih.gov/pubmed/36648627
http://dx.doi.org/10.1007/s15010-022-01959-9